Eyenovia, Inc. announced on February 24, 2025, that it has entered into an amendment to its outstanding senior secured convertible debt, originally due November 1, 2025. This amendment defers the company’s monthly interest and amortization payments from March 2025 through September 2025.
The amendment also allows for the full conversion of the debt into common shares of the company, commencing on April 1, 2025, at a price of $1.68 per share. This restructuring is intended to strengthen Eyenovia’s capital structure and improve its near-term liquidity position.
Michael Rowe, CEO of Eyenovia, stated that this amendment enhances the company's ability to continue developing its user-filled Optejet device towards a potential near-term regulatory filing. It also provides flexibility while the company evaluates strategic alternatives to maximize shareholder value.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.